Albireo Financial Statements From 2010 to 2022

ALBO
 Stock
  

USD 21.78  0.35  1.63%   

Albireo Pharma financial statements provide useful quarterly and yearly information to potential Albireo Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Albireo Pharma financial statements helps investors assess Albireo Pharma's valuation, profitability, and current liquidity needs.
We have found ninety-one available fundamental signals for Albireo Pharma, which can be analyzed and compared to other ratios and to its rivals. We recommend to validate Albireo Pharma's prevailing fundamental drivers against the all of the trends between 2010 and 2022.
Albireo Pharma Revenue Per Employee is quite stable at the moment as compared to the past year. The company's current value of Revenue Per Employee is estimated at 335,837. Average Assets is expected to rise to about 288 M this year, although the value of Net Income Per Employee will most likely fall to (282.4 K).
  
Check Albireo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Albireo main balance sheet or income statement drivers, such as Direct Expenses of 1.2 M, Cost of Revenue of 1.2 M or Gross Profit of 42.3 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0531, PPandE Turnover of 61.97 or Receivables Turnover of 6.79. Albireo financial statements analysis is a perfect complement when working with Albireo Pharma Valuation or Volatility modules. It can also supplement Albireo Pharma's financial leverage analysis and stock options assessment as well as various Albireo Pharma Technical models . Please continue to the analysis of Albireo Pharma Correlation against competitors.

Albireo Pharma Revenues

43.78 Million

Albireo Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Tax Liabilities74.7 K67.5 K78.6 K
Decreasing
Slightly volatile
Tax Assets5.5 K5.4 K10.3 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables4.1 M3.8 M1.8 M
Increasing
Slightly volatile
Property Plant and Equipment Net637.9 K668 K627.1 K
Decreasing
Slightly volatile
Trade and Non Trade PayablesM6.5 M2.7 M
Increasing
Slightly volatile
Liabilities Non Current87.5 M81.1 M29.2 M
Increasing
Slightly volatile
Current Liabilities48.9 M45.3 M14.4 M
Increasing
Slightly volatile
Total Liabilities136.4 M126.4 M42.8 M
Increasing
Slightly volatile
Inventory173.6 K174.6 K190.9 K
Decreasing
Slightly volatile
Goodwill and Intangible Assets16.5 M19.8 M12.3 M
Increasing
Slightly volatile
Shareholders Equity USD189.5 M175.6 M74.6 M
Increasing
Slightly volatile
Shareholders Equity189.5 M175.6 M80.1 M
Increasing
Slightly volatile
Total Debt USD9.6 M10 M8.1 M
Increasing
Slightly volatile
Debt Non Current10 M10 M7.5 M
Increasing
Slightly volatile
Debt Current3.5 M3.5 M2.9 M
Increasing
Slightly volatile
Total Debt9.6 M10 M8.1 M
Increasing
Slightly volatile
Cash and Equivalents USD267.7 M248.1 M99.9 M
Increasing
Slightly volatile
Cash and Equivalents267.7 M248.1 M103.2 M
Increasing
Slightly volatile
Assets Non Current35.7 M33.1 M13.6 M
Increasing
Slightly volatile
Current Assets290.2 M268.9 M109.3 M
Increasing
Slightly volatile
Total Assets325.9 M302.1 M122.9 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income974.9 K1.1 M887.2 K
Decreasing
Very volatile
Accounts PayableM6.5 M2.6 M
Increasing
Slightly volatile
Receivables3.2 M2.9 M1.4 M
Increasing
Slightly volatile
Inventories173.6 K174.6 K190.9 K
Decreasing
Slightly volatile

Albireo Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Income Tax Expense23.6 K23 K46.5 K
Decreasing
Very volatile
Weighted Average Shares Diluted20.7 M19.2 M7.3 M
Increasing
Slightly volatile
Weighted Average Shares20.7 M19.2 M7.3 M
Increasing
Slightly volatile
Selling General and Administrative Expense75.1 M69.6 M22.9 M
Increasing
Slightly volatile
Research and Development Expense89 M82.5 M31.7 M
Increasing
Slightly volatile
Revenues USD43.8 M40.6 M12.1 M
Increasing
Slightly volatile
Revenues43.8 M40.6 M15 M
Increasing
Slightly volatile
Operating Expenses175.6 M162.7 M55 M
Increasing
Slightly volatile
Interest Expense15 M13.9 M4.8 M
Increasing
Slightly volatile
Gross Profit42.3 M39.2 M11.9 M
Increasing
Slightly volatile
Cost of Revenue1.2 M1.2 M1.3 M
Decreasing
Slightly volatile
Direct Expenses1.2 M1.2 M1.3 M
Decreasing
Slightly volatile

Albireo Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Share Based Compensation17.2 M15.9 M5.9 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (1.3 M)(1.3 M)(613.1 K)
Decreasing
Stable
Net Cash Flow Investment Acquisitions and Disposals5.4 M5.4 M5.9 M
Decreasing
Slightly volatile
Net Cash Flow from Investing111 M102.9 M18.2 M
Increasing
Slightly volatile
Net Cash Flow from Financing2.8 M2.8 M40.4 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 11.8 M10.9 M4.8 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares2.8 M2.8 M32.4 M
Increasing
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals99.9 M118.9 M62.4 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(3.2 M)(3.2 M)18.1 M
Increasing
Stable
Depreciation Amortization and Accretion282.4 K274 K300.5 K
Decreasing
Slightly volatile
Capital Expenditure(477.2 K)(465 K)175.3 K
Decreasing
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Tangible Assets Book Value per Share15.2114.81741.9539
Decreasing
Slightly volatile
Sales per Share2.432.11125.4548
Decreasing
Slightly volatile
Return on Invested Capital19.2623.04816.2754
Decreasing
Slightly volatile
Price to Sales Ratio11.3211.03215.4 K
Increasing
Very volatile
Price to Book Value2.492.5571.6731
Increasing
Slightly volatile
Gross Margin86.4886.9995.132
Decreasing
Slightly volatile
Enterprise Value over EBITDA(10.16)(9.903)(2.731)
Decreasing
Slightly volatile
Enterprise Value over EBIT(10.26)(10.0)(2.8664)
Decreasing
Slightly volatile
Debt to Equity Ratio0.06720.0570.0707
Decreasing
Slightly volatile
Current Ratio6.085.930510.9041
Decreasing
Slightly volatile
Book Value per Share9.389.13626.3712
Decreasing
Slightly volatile
Asset Turnover0.130.13810.1693
Decreasing
Slightly volatile
Total Assets Per Share16.0615.653134.7441
Decreasing
Slightly volatile
Receivables Turnover6.796.32.6234
Increasing
Slightly volatile
PPandE Turnover61.9770.818559.2092
Decreasing
Slightly volatile
Cash and Equivalents Turnover0.150.16250.2142
Decreasing
Slightly volatile
Accounts Payable Turnover6.656.878410.4345
Decreasing
Slightly volatile
Accrued Expenses Turnover1.471.47551.8376
Decreasing
Slightly volatile
Long Term Debt to Equity0.05310.0570.0534
Increasing
Slightly volatile
Quick Ratio7.635.37478.1497
Decreasing
Stable
Net Current Assets as percentage of Total Assets85.2574.021679.8507
Decreasing
Stable
Revenue to Assets0.120.13430.1549
Decreasing
Slightly volatile

Albireo Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Working Capital241.2 M223.6 M90.4 M
Increasing
Slightly volatile
Tangible Asset Value307.3 M284.8 M109.8 M
Increasing
Slightly volatile
Market Capitalization357.5 M449 M206.3 M
Increasing
Slightly volatile
Invested Capital Average(940.8 K)(872 K)(1.5 M)
Decreasing
Stable
Invested Capital1.4 M1.3 M(1.7 M)
Increasing
Very volatile
Enterprise Value165.7 M196.3 M102.5 M
Increasing
Slightly volatile
Average Equity122.4 M154.7 M71 M
Increasing
Slightly volatile
Average Assets288 M267 M113.1 M
Increasing
Slightly volatile
Revenue Per Employee335.8 K312.1 K564.9 K
Decreasing
Slightly volatile

Albireo Fundamental Market Drivers

Short Percent Of Float11.90%
Forward Price Earnings-3.40
Shares Short Prior Month2.1M
Average Daily Volume Last 10 Day149.17k
Average Daily Volume In Three Month372k
Date Short Interest14th of October 2022
Fifty Day Average20.54
Two Hundred Day Average24.39

Albireo Upcoming Events

Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Albireo Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Albireo Pharma income statement, its balance sheet, and the statement of cash flows. Albireo Pharma investors use historical funamental indicators, such as Albireo Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Albireo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Albireo Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Cost of Revenue1.2 M1.2 M
Revenues40.6 M43.8 M
Revenue to Assets 0.13  0.12 
Revenue Per Employee312.1 K335.8 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of Albireo Pharma Correlation against competitors. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
454.3 M
Quarterly Revenue Growth YOY
1.68
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.